))
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Manage episode 416912152 series 3382903
Innehåll tillhandahållet av ReachMD. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av ReachMD eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Host: Arshad M. Khanani, MD, MA
Guest: Karl Csaky, MD, PhD
Guest: Christina Y. Weng, MD, MBA, FASRS
Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices.
…
continue reading
Guest: Karl Csaky, MD, PhD
Guest: Christina Y. Weng, MD, MBA, FASRS
Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal vascular diseases. Dual inhibition therapy that acts on 2 pathways—VEGF-A and angiopoietin-2 (Ang-2)—is now available. Are 2 pathways better than 1? Find out in this engaging roundtable-style eye care forum, which will demonstrate direct comparisons of dual anti-Ang-2/VEGF-A therapy and anti-VEGF monotherapy, enhanced by real-life case studies and anecdotes from the expert faculty members’ own practices.
704 episoder
Dela
